Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-associated Malignancies Clinical Trial

Official title:
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Status Completed

Clinical Trial Summary

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

EBV-associated Malignancies
EBV-induced Lymphomas
Epstein-Barr Virus Infections
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Viremia

Clinical Trial Details

NCT number	NCT01498484
Study type	Interventional
Source	Atara Biotherapeutics
Contact
Status	Completed
Phase	Phase 2
Start date	December 2011
Completion date	July 2019

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00002663` - Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies	Phase 1/Phase 2
	Withdrawn	`NCT03988582` - Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies	Phase 2